<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15386">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02906579</url>
  </required_header>
  <id_info>
    <org_study_id>C1973-201</org_study_id>
    <nct_id>NCT02906579</nct_id>
  </id_info>
  <brief_title>A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension</brief_title>
  <official_title>An Open-label, Phase 2a Trial to Evaluate the Effect of Escalating Doses of IW-1973 on Tolerability, Endothelial Function, and Hemodynamics in Patients With Stable Type 2 Diabetes and Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ironwood Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ironwood Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      To evaluate the impact of escalating doses of IW-1973 on endothelial function [using EndoPAT
      to measure fingertip small vessel pulse volume], blood pressure (BP), and heart rate.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>49 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in systolic and diastolic BP and heart rate measurements</measure>
    <time_frame>19 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Endothelial Function as assessed by EndoPAT evaluation</measure>
    <time_frame>19 Days</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo taken once daily Day 1-Day 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg IW-1973</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg IW-1973 take once daily Day 4-Day 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg IW-1973</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg IW-1973 taken once daily Day 7-Day 9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg IW-1973</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg IW-1973 taken once daily Day 10-Day 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg IW-1973</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg IW-1973 taken once daily Day 13-Day 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg IW-1973</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg IW-1973 taken once daily Day 16-Day 18</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IW-1973</intervention_name>
    <arm_group_label>10 mg IW-1973</arm_group_label>
    <arm_group_label>20 mg IW-1973</arm_group_label>
    <arm_group_label>30 mg IW-1973</arm_group_label>
    <arm_group_label>40 mg IW-1973</arm_group_label>
    <arm_group_label>50 mg IW-1973</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is ambulatory male or female

          -  Patient's body mass index score is &gt;20 and &lt;40 kg/m2 at the Screening Visit

          -  Women of childbearing potential must have a negative pregnancy test at the time of
             check-in and must agree to use double-barrier contraception throughout the duration
             of the study

          -  Patient's health is stable with no clinically significant findings on a physical
             examination

          -  Patient has type 2 (ie adult onset) diabetes mellitus diagnosed by a physician or
             nurse practitioner &gt; 6 months before the Screening Visit, and an entry HbA1c that
             does not mandate prompt intervention for improved control

          -  Patient has hypertension diagnosed by a physician or nurse pratictioner &gt; 6 months
             before the Screening Visit and BP within the protocol's acceptable range

          -  Patients must be on a stable regimen for glycemic control, and a stable regimen for
             hypertension control that includes an angiotensin converting enzyme inhibitor (ACEi)
             or angiotensin receptor blocker (ARB)

          -  Patient has abnormal endothelial function measured by the EndoPAT

          -  Other inclusion criteria per protocol

        Exclusion Criteria:

          -  Patient has a clinically significant active or unstable medical condition that, in
             the opinion of the Investigator, would preclude trial participation

          -  Patient is on medication(s) that when co-administered with a soluble guanylate
             cyclase (sGC) stimulator, could increase the risk of hypotension

          -  Patient has evidence of severe or active end-organ damage attributable to diabetes

          -  Patient has severe renal insufficiency, has undergone renal transplantation, or has
             planned renal transplantation

          -  Other exclusion criteria per protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dennis Ruff, MD</last_name>
    <phone>210-798-5106</phone>
  </overall_contact>
  <location>
    <facility>
      <name>ICON Early Phase Unit</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>210-798-5106</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 1, 2017</lastchanged_date>
  <firstreceived_date>September 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
